Emerging concepts in biomarker discovery; The US-Japan workshop on immunological molecular markers in oncology

Hideaki Tahara, Marimo Sato, Magdalena Thurin, Ena Wang, Lisa H. Butterfield, Mary L. Disis, Bernard A. Fox, Peter P. Lee, Samir N. Khleif, Jon M. Wigginton, Stefan Ambs, Yasunori Akutsu, Damien J. Chaussabel, Yuichiro Doki, Oleg Eremin, Wolf Herevé Fridman, Yoshihiko Hirohashi, Kohzoh Imai, James Jacobson, Masahisa Jinushi & 36 others Akira Kanamoto, Mohammed Kashani-Sabet, Kazunori Kato, Yutaka Kawakami, John M. Kirkwood, Thomas O. Kleen, Paul V. Lehmann, Lance Liotta, Michael T. Lotze, Michele Maio, Anatoli Malyguine, Giuseppe Masucci, Hisahiro Matsubara, Shawmarie Mayrand-Chung, Kiminori Nakamura, Hiroyoshi Nishikawa, A. Karolina Karolina, Emanuel F. Petricoin, Zoltan Pos, Antoni Ribas, Licia Rivoltini, Noriyuki Sato, Hiroshi Shiku, Craig L. Slingluff, Howard Streicher, David F. Stroncek, Hiroya Takeuchi, Minoru Toyota, Hisashi Wada, Xifeng Wu, Julia Wulfkuhle, Tomonori Yaguchi, Benjamin Zeskind, Yingdong Zhao, Mai Britt Zocca, Francesco M. Marincola

Research output: Contribution to journalArticle

39 Citations (Scopus)

Abstract

Supported by the Office of International Affairs, National Cancer Institute (NCI), the "US-Japan Workshop on Immunological Biomarkers in Oncology" was held in March 2009. The workshop was related to a task force launched by the International Society for the Biological Therapy of Cancer (iSBTc) and the United States Food and Drug Administration (FDA) to identify strategies for biomarker discovery and validation in the field of biotherapy. The effort will culminate on October 28th 2009 in the "iSBTc-FDA-NCI Workshop on Prognostic and Predictive Immunologic Biomarkers in Cancer", which will be held in Washington DC in association with the Annual Meeting. The purposes of the US-Japan workshop were a) to discuss novel approaches to enhance the discovery of predictive and/or prognostic markers in cancer immunotherapy; b) to define the state of the science in biomarker discovery and validation. The participation of Japanese and US scientists provided the opportunity to identify shared or discordant themes across the distinct immune genetic background and the diverse prevalence of disease between the two Nations. Converging concepts were identified: enhanced knowledge of interferon-related pathways was found to be central to the understanding of immune-mediated tissue-specific destruction (TSD) of which tumor rejection is a representative facet. Although the expression of interferon-stimulated genes (ISGs) likely mediates the inflammatory process leading to tumor rejection, it is insufficient by itself and the associated mechanisms need to be identified. It is likely that adaptive immune responses play a broader role in tumor rejection than those strictly related to their antigen-specificity; likely, their primary role is to trigger an acute and tissue-specific inflammatory response at the tumor site that leads to rejection upon recruitment of additional innate and adaptive immune mechanisms. Other candidate systemic and/or tissue-specific biomarkers were recognized that might be added to the list of known entities applicable in immunotherapy trials. The need for a systematic approach to biomarker discovery that takes advantage of powerful high-throughput technologies was recognized; it was clear from the current state of the science that immunotherapy is still in a discovery phase and only a few of the current biomarkers warrant extensive validation. It was, finally, clear that, while current technologies have almost limitless potential, inadequate study design, limited standardization and cross-validation among laboratories and suboptimal comparability of data remain major road blocks. The institution of an interactive consortium for high throughput molecular monitoring of clinical trials with voluntary participation might provide cost-effective solutions.

Original languageEnglish
Article number45
JournalJournal of Translational Medicine
Volume7
DOIs
Publication statusPublished - 17 Jun 2009
Externally publishedYes

Fingerprint

Oncology
Biomarkers
Japan
Education
Biological Therapy
Tumors
Neoplasms
Immunotherapy
National Cancer Institute (U.S.)
United States Food and Drug Administration
Tissue
Interferons
Throughput
Technology
Adaptive Immunity
Advisory Committees
Tumor Biomarkers
Standardization
Genes
Association reactions

ASJC Scopus subject areas

  • Medicine(all)
  • Biochemistry, Genetics and Molecular Biology(all)

Cite this

Emerging concepts in biomarker discovery; The US-Japan workshop on immunological molecular markers in oncology. / Tahara, Hideaki; Sato, Marimo; Thurin, Magdalena; Wang, Ena; Butterfield, Lisa H.; Disis, Mary L.; Fox, Bernard A.; Lee, Peter P.; Khleif, Samir N.; Wigginton, Jon M.; Ambs, Stefan; Akutsu, Yasunori; Chaussabel, Damien J.; Doki, Yuichiro; Eremin, Oleg; Fridman, Wolf Herevé; Hirohashi, Yoshihiko; Imai, Kohzoh; Jacobson, James; Jinushi, Masahisa; Kanamoto, Akira; Kashani-Sabet, Mohammed; Kato, Kazunori; Kawakami, Yutaka; Kirkwood, John M.; Kleen, Thomas O.; Lehmann, Paul V.; Liotta, Lance; Lotze, Michael T.; Maio, Michele; Malyguine, Anatoli; Masucci, Giuseppe; Matsubara, Hisahiro; Mayrand-Chung, Shawmarie; Nakamura, Kiminori; Nishikawa, Hiroyoshi; Karolina, A. Karolina; Petricoin, Emanuel F.; Pos, Zoltan; Ribas, Antoni; Rivoltini, Licia; Sato, Noriyuki; Shiku, Hiroshi; Slingluff, Craig L.; Streicher, Howard; Stroncek, David F.; Takeuchi, Hiroya; Toyota, Minoru; Wada, Hisashi; Wu, Xifeng; Wulfkuhle, Julia; Yaguchi, Tomonori; Zeskind, Benjamin; Zhao, Yingdong; Zocca, Mai Britt; Marincola, Francesco M.

In: Journal of Translational Medicine, Vol. 7, 45, 17.06.2009.

Research output: Contribution to journalArticle

Tahara, H, Sato, M, Thurin, M, Wang, E, Butterfield, LH, Disis, ML, Fox, BA, Lee, PP, Khleif, SN, Wigginton, JM, Ambs, S, Akutsu, Y, Chaussabel, DJ, Doki, Y, Eremin, O, Fridman, WH, Hirohashi, Y, Imai, K, Jacobson, J, Jinushi, M, Kanamoto, A, Kashani-Sabet, M, Kato, K, Kawakami, Y, Kirkwood, JM, Kleen, TO, Lehmann, PV, Liotta, L, Lotze, MT, Maio, M, Malyguine, A, Masucci, G, Matsubara, H, Mayrand-Chung, S, Nakamura, K, Nishikawa, H, Karolina, AK, Petricoin, EF, Pos, Z, Ribas, A, Rivoltini, L, Sato, N, Shiku, H, Slingluff, CL, Streicher, H, Stroncek, DF, Takeuchi, H, Toyota, M, Wada, H, Wu, X, Wulfkuhle, J, Yaguchi, T, Zeskind, B, Zhao, Y, Zocca, MB & Marincola, FM 2009, 'Emerging concepts in biomarker discovery; The US-Japan workshop on immunological molecular markers in oncology', Journal of Translational Medicine, vol. 7, 45. https://doi.org/10.1186/1479-5876-7-45
Tahara, Hideaki ; Sato, Marimo ; Thurin, Magdalena ; Wang, Ena ; Butterfield, Lisa H. ; Disis, Mary L. ; Fox, Bernard A. ; Lee, Peter P. ; Khleif, Samir N. ; Wigginton, Jon M. ; Ambs, Stefan ; Akutsu, Yasunori ; Chaussabel, Damien J. ; Doki, Yuichiro ; Eremin, Oleg ; Fridman, Wolf Herevé ; Hirohashi, Yoshihiko ; Imai, Kohzoh ; Jacobson, James ; Jinushi, Masahisa ; Kanamoto, Akira ; Kashani-Sabet, Mohammed ; Kato, Kazunori ; Kawakami, Yutaka ; Kirkwood, John M. ; Kleen, Thomas O. ; Lehmann, Paul V. ; Liotta, Lance ; Lotze, Michael T. ; Maio, Michele ; Malyguine, Anatoli ; Masucci, Giuseppe ; Matsubara, Hisahiro ; Mayrand-Chung, Shawmarie ; Nakamura, Kiminori ; Nishikawa, Hiroyoshi ; Karolina, A. Karolina ; Petricoin, Emanuel F. ; Pos, Zoltan ; Ribas, Antoni ; Rivoltini, Licia ; Sato, Noriyuki ; Shiku, Hiroshi ; Slingluff, Craig L. ; Streicher, Howard ; Stroncek, David F. ; Takeuchi, Hiroya ; Toyota, Minoru ; Wada, Hisashi ; Wu, Xifeng ; Wulfkuhle, Julia ; Yaguchi, Tomonori ; Zeskind, Benjamin ; Zhao, Yingdong ; Zocca, Mai Britt ; Marincola, Francesco M. / Emerging concepts in biomarker discovery; The US-Japan workshop on immunological molecular markers in oncology. In: Journal of Translational Medicine. 2009 ; Vol. 7.
@article{ca781a4ec6684d14a779c959994a84e7,
title = "Emerging concepts in biomarker discovery; The US-Japan workshop on immunological molecular markers in oncology",
abstract = "Supported by the Office of International Affairs, National Cancer Institute (NCI), the {"}US-Japan Workshop on Immunological Biomarkers in Oncology{"} was held in March 2009. The workshop was related to a task force launched by the International Society for the Biological Therapy of Cancer (iSBTc) and the United States Food and Drug Administration (FDA) to identify strategies for biomarker discovery and validation in the field of biotherapy. The effort will culminate on October 28th 2009 in the {"}iSBTc-FDA-NCI Workshop on Prognostic and Predictive Immunologic Biomarkers in Cancer{"}, which will be held in Washington DC in association with the Annual Meeting. The purposes of the US-Japan workshop were a) to discuss novel approaches to enhance the discovery of predictive and/or prognostic markers in cancer immunotherapy; b) to define the state of the science in biomarker discovery and validation. The participation of Japanese and US scientists provided the opportunity to identify shared or discordant themes across the distinct immune genetic background and the diverse prevalence of disease between the two Nations. Converging concepts were identified: enhanced knowledge of interferon-related pathways was found to be central to the understanding of immune-mediated tissue-specific destruction (TSD) of which tumor rejection is a representative facet. Although the expression of interferon-stimulated genes (ISGs) likely mediates the inflammatory process leading to tumor rejection, it is insufficient by itself and the associated mechanisms need to be identified. It is likely that adaptive immune responses play a broader role in tumor rejection than those strictly related to their antigen-specificity; likely, their primary role is to trigger an acute and tissue-specific inflammatory response at the tumor site that leads to rejection upon recruitment of additional innate and adaptive immune mechanisms. Other candidate systemic and/or tissue-specific biomarkers were recognized that might be added to the list of known entities applicable in immunotherapy trials. The need for a systematic approach to biomarker discovery that takes advantage of powerful high-throughput technologies was recognized; it was clear from the current state of the science that immunotherapy is still in a discovery phase and only a few of the current biomarkers warrant extensive validation. It was, finally, clear that, while current technologies have almost limitless potential, inadequate study design, limited standardization and cross-validation among laboratories and suboptimal comparability of data remain major road blocks. The institution of an interactive consortium for high throughput molecular monitoring of clinical trials with voluntary participation might provide cost-effective solutions.",
author = "Hideaki Tahara and Marimo Sato and Magdalena Thurin and Ena Wang and Butterfield, {Lisa H.} and Disis, {Mary L.} and Fox, {Bernard A.} and Lee, {Peter P.} and Khleif, {Samir N.} and Wigginton, {Jon M.} and Stefan Ambs and Yasunori Akutsu and Chaussabel, {Damien J.} and Yuichiro Doki and Oleg Eremin and Fridman, {Wolf Herev{\'e}} and Yoshihiko Hirohashi and Kohzoh Imai and James Jacobson and Masahisa Jinushi and Akira Kanamoto and Mohammed Kashani-Sabet and Kazunori Kato and Yutaka Kawakami and Kirkwood, {John M.} and Kleen, {Thomas O.} and Lehmann, {Paul V.} and Lance Liotta and Lotze, {Michael T.} and Michele Maio and Anatoli Malyguine and Giuseppe Masucci and Hisahiro Matsubara and Shawmarie Mayrand-Chung and Kiminori Nakamura and Hiroyoshi Nishikawa and Karolina, {A. Karolina} and Petricoin, {Emanuel F.} and Zoltan Pos and Antoni Ribas and Licia Rivoltini and Noriyuki Sato and Hiroshi Shiku and Slingluff, {Craig L.} and Howard Streicher and Stroncek, {David F.} and Hiroya Takeuchi and Minoru Toyota and Hisashi Wada and Xifeng Wu and Julia Wulfkuhle and Tomonori Yaguchi and Benjamin Zeskind and Yingdong Zhao and Zocca, {Mai Britt} and Marincola, {Francesco M.}",
year = "2009",
month = "6",
day = "17",
doi = "10.1186/1479-5876-7-45",
language = "English",
volume = "7",
journal = "Journal of Translational Medicine",
issn = "1479-5876",
publisher = "BioMed Central",

}

TY - JOUR

T1 - Emerging concepts in biomarker discovery; The US-Japan workshop on immunological molecular markers in oncology

AU - Tahara, Hideaki

AU - Sato, Marimo

AU - Thurin, Magdalena

AU - Wang, Ena

AU - Butterfield, Lisa H.

AU - Disis, Mary L.

AU - Fox, Bernard A.

AU - Lee, Peter P.

AU - Khleif, Samir N.

AU - Wigginton, Jon M.

AU - Ambs, Stefan

AU - Akutsu, Yasunori

AU - Chaussabel, Damien J.

AU - Doki, Yuichiro

AU - Eremin, Oleg

AU - Fridman, Wolf Herevé

AU - Hirohashi, Yoshihiko

AU - Imai, Kohzoh

AU - Jacobson, James

AU - Jinushi, Masahisa

AU - Kanamoto, Akira

AU - Kashani-Sabet, Mohammed

AU - Kato, Kazunori

AU - Kawakami, Yutaka

AU - Kirkwood, John M.

AU - Kleen, Thomas O.

AU - Lehmann, Paul V.

AU - Liotta, Lance

AU - Lotze, Michael T.

AU - Maio, Michele

AU - Malyguine, Anatoli

AU - Masucci, Giuseppe

AU - Matsubara, Hisahiro

AU - Mayrand-Chung, Shawmarie

AU - Nakamura, Kiminori

AU - Nishikawa, Hiroyoshi

AU - Karolina, A. Karolina

AU - Petricoin, Emanuel F.

AU - Pos, Zoltan

AU - Ribas, Antoni

AU - Rivoltini, Licia

AU - Sato, Noriyuki

AU - Shiku, Hiroshi

AU - Slingluff, Craig L.

AU - Streicher, Howard

AU - Stroncek, David F.

AU - Takeuchi, Hiroya

AU - Toyota, Minoru

AU - Wada, Hisashi

AU - Wu, Xifeng

AU - Wulfkuhle, Julia

AU - Yaguchi, Tomonori

AU - Zeskind, Benjamin

AU - Zhao, Yingdong

AU - Zocca, Mai Britt

AU - Marincola, Francesco M.

PY - 2009/6/17

Y1 - 2009/6/17

N2 - Supported by the Office of International Affairs, National Cancer Institute (NCI), the "US-Japan Workshop on Immunological Biomarkers in Oncology" was held in March 2009. The workshop was related to a task force launched by the International Society for the Biological Therapy of Cancer (iSBTc) and the United States Food and Drug Administration (FDA) to identify strategies for biomarker discovery and validation in the field of biotherapy. The effort will culminate on October 28th 2009 in the "iSBTc-FDA-NCI Workshop on Prognostic and Predictive Immunologic Biomarkers in Cancer", which will be held in Washington DC in association with the Annual Meeting. The purposes of the US-Japan workshop were a) to discuss novel approaches to enhance the discovery of predictive and/or prognostic markers in cancer immunotherapy; b) to define the state of the science in biomarker discovery and validation. The participation of Japanese and US scientists provided the opportunity to identify shared or discordant themes across the distinct immune genetic background and the diverse prevalence of disease between the two Nations. Converging concepts were identified: enhanced knowledge of interferon-related pathways was found to be central to the understanding of immune-mediated tissue-specific destruction (TSD) of which tumor rejection is a representative facet. Although the expression of interferon-stimulated genes (ISGs) likely mediates the inflammatory process leading to tumor rejection, it is insufficient by itself and the associated mechanisms need to be identified. It is likely that adaptive immune responses play a broader role in tumor rejection than those strictly related to their antigen-specificity; likely, their primary role is to trigger an acute and tissue-specific inflammatory response at the tumor site that leads to rejection upon recruitment of additional innate and adaptive immune mechanisms. Other candidate systemic and/or tissue-specific biomarkers were recognized that might be added to the list of known entities applicable in immunotherapy trials. The need for a systematic approach to biomarker discovery that takes advantage of powerful high-throughput technologies was recognized; it was clear from the current state of the science that immunotherapy is still in a discovery phase and only a few of the current biomarkers warrant extensive validation. It was, finally, clear that, while current technologies have almost limitless potential, inadequate study design, limited standardization and cross-validation among laboratories and suboptimal comparability of data remain major road blocks. The institution of an interactive consortium for high throughput molecular monitoring of clinical trials with voluntary participation might provide cost-effective solutions.

AB - Supported by the Office of International Affairs, National Cancer Institute (NCI), the "US-Japan Workshop on Immunological Biomarkers in Oncology" was held in March 2009. The workshop was related to a task force launched by the International Society for the Biological Therapy of Cancer (iSBTc) and the United States Food and Drug Administration (FDA) to identify strategies for biomarker discovery and validation in the field of biotherapy. The effort will culminate on October 28th 2009 in the "iSBTc-FDA-NCI Workshop on Prognostic and Predictive Immunologic Biomarkers in Cancer", which will be held in Washington DC in association with the Annual Meeting. The purposes of the US-Japan workshop were a) to discuss novel approaches to enhance the discovery of predictive and/or prognostic markers in cancer immunotherapy; b) to define the state of the science in biomarker discovery and validation. The participation of Japanese and US scientists provided the opportunity to identify shared or discordant themes across the distinct immune genetic background and the diverse prevalence of disease between the two Nations. Converging concepts were identified: enhanced knowledge of interferon-related pathways was found to be central to the understanding of immune-mediated tissue-specific destruction (TSD) of which tumor rejection is a representative facet. Although the expression of interferon-stimulated genes (ISGs) likely mediates the inflammatory process leading to tumor rejection, it is insufficient by itself and the associated mechanisms need to be identified. It is likely that adaptive immune responses play a broader role in tumor rejection than those strictly related to their antigen-specificity; likely, their primary role is to trigger an acute and tissue-specific inflammatory response at the tumor site that leads to rejection upon recruitment of additional innate and adaptive immune mechanisms. Other candidate systemic and/or tissue-specific biomarkers were recognized that might be added to the list of known entities applicable in immunotherapy trials. The need for a systematic approach to biomarker discovery that takes advantage of powerful high-throughput technologies was recognized; it was clear from the current state of the science that immunotherapy is still in a discovery phase and only a few of the current biomarkers warrant extensive validation. It was, finally, clear that, while current technologies have almost limitless potential, inadequate study design, limited standardization and cross-validation among laboratories and suboptimal comparability of data remain major road blocks. The institution of an interactive consortium for high throughput molecular monitoring of clinical trials with voluntary participation might provide cost-effective solutions.

UR - http://www.scopus.com/inward/record.url?scp=69049087185&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=69049087185&partnerID=8YFLogxK

U2 - 10.1186/1479-5876-7-45

DO - 10.1186/1479-5876-7-45

M3 - Article

VL - 7

JO - Journal of Translational Medicine

JF - Journal of Translational Medicine

SN - 1479-5876

M1 - 45

ER -